Researchers have developed a new model to predict the effect of treatment with direct-acting antivirals over time.
The finding raises the possibility of greatly reducing, and even eliminating, hepatitis C if enhanced screening and treatment efforts target high-risk populations -- injection-drug users.
The direct-acting antivirals have the potential to significantly reduce or eliminate HCV in two ways -- through treatment to prevent HCV-related complications and deaths, and by preventing further transmission among injection-drug users.
More modest increases in screening and treatment would also markedly reduce new infections and mortality, the researchers determined.
"We should be very optimistic about the prospect of eliminating HCV as a disease within the US using these direct acting antivirals, especially if they are combined with targeted behavioural interventions to reduce transmission," Townsend said.
However, he added, "due to the currently high cost of these treatments, as a society we need to think carefully about how to make that happen".
The study was published online in the journal Clinical Infectious Diseases.